KBC Group’s iShares Biotechnology ETF IBB Stock Holding History

KBC Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-827	Closed	-$125K	–	1296
2021 Q1	$125K	Buy	+827	New	+$131K	﹤0.01%	1153

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

KBC Group's IBB Position: Q2 2021 in Review

KBC Group sold out of iShares Biotechnology ETF (IBB) in Q2 2021, closing a stake of 827 shares — an estimated $125K sold.

KBC Group first reported a position in IBB in Q1 2021 and held it in 1 quarter. The position peaked at $125K in Q1 2021. 864 funds tracked by Wall St. Rank hold IBB as of Q2 2021.

KBC Group reported no remaining iShares Biotechnology ETF position as of Q2 2021 after selling out during the quarter.
KBC Group sold 827 iShares Biotechnology ETF shares in Q2 2021, an estimated $125K.
KBC Group first reported a position in iShares Biotechnology ETF in Q1 2021 and held it in 1 quarter.
KBC Group's iShares Biotechnology ETF position peaked at $125K in Q1 2021.
864 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2021.

Based on KBC Group's 13F filing for Q2 2021, filed 11 Aug 2021.